Lupus Nephritis Pipeline Outlook Report 2025: Tracking the Most Promising Drugs in Clinical Development | DelveInsight

DelveInsight's "Lupus Nephritis Pipeline Insight 2025" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Lupus Nephritis pipeline landscape. It covers the Lupus Nephritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Lupus Nephritis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Lupus Nephritis Pipeline? Click here to explore the therapies and trials making headlines @ Lupus Nephritis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Lupus Nephritis Pipeline Report

* On 27 October 2025, Novartis Pharmaceuticals announced a study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).
* On 20 October 2025, AstraZeneca conducted a study to evaluate the efficacy and safety of anifrolumab versus placebo as added to SOC (consisting of MMF and glucocorticoids) in adults with active proliferative Class III or Class IV LN (both with or without concomitant Class V). The total study duration may be up to approximately 116 weeks, including the Screening and Follow-up. Approximately 360 participants will be randomized in a 1:1 ratio to receive anifrolumab or matching placebo throughout during the Treatment Period.
* On 20 October 2025, HI-Bio, A Biogen Company organized a study drug called felzartamab affects people with LN. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce antibodies, helping to lower their buildup in the kidneys. The main goal of this study is to learn more about the safety of felzartamab and how it works in the body of people with LN who are taking standard of care. This will help researchers decide if they should do more studies with felzartamab in people with LN. Standard of care is the usual treatment or care given to patients for a disease, as prescribed by their doctor.
* DelveInsight's Lupus Nephritis Pipeline report depicts a robust space with 35+ active players working to develop 40+ pipeline therapies for Lupus Nephritis treatment.
* The leading Lupus Nephritis Companies such as Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics, Annexon, Century Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, Inflection Biosciences and others.
* Promising Lupus Nephritis Therapies such as Ciclesonide, Niclosamide, Povetacicept, APL-2, Belimumab Injection, AZD0120, Cyclophosphamide, Fludarabine, AZD0120, Abetimus sodium (LJP 394) , and others.

Want to know which companies are leading innovation in Lupus Nephritis? Dive into the full pipeline insights @ Lupus Nephritis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Lupus Nephritis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Lupus Nephritis Pipeline Report also highlights the unmet needs with respect to the Lupus Nephritis.

Lupus Nephritis Overview

Lupus Nephritis (LN), is one of the most severe organ manifestations of systemic lupus erythematosus (SLE) which is an autoimmune disorder leading to the loss of immune tolerance of endogenous nuclear material resulting in systemic autoimmunity that causes damage to various tissues and organs. The overall incidence and prevalence of SLE ranges 7.4-159.4 cases per 100,000 people and from 1.4 to 21.9 %, respectively. According to National Kidney Foundation, Lupus nephritis (LN) is a form of glomerulonephritis that causes inflammation (swelling or scarring) of the small blood vessels that filter wastes in the kidney (glomeruli) and sometimes the kidneys itself. Histologically LN is classified into six distinct classes representing different manifestations and severity of renal involvement in SLE. Lupus nephritis can cause permanent kidney damage, called chronic kidney disease or CKD. The most serious type of lupus nephritis is proliferative nephritis, which can cause scarring of the kidneys. These scars can damage the kidneys and prevent them from working properly. Chronic kidney disease that gets worse and causes the kidneys to stop working is called kidney failure or end-stage renal disease (ESRD).

Lupus Nephritis Emerging Drugs Profile

* Obinutuzumab: Hoffmann-La Roche

Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche. Obinutuzumab has a distinct mode of action relative to type I anti-CD20 antibodies, such as rituximab, working primarily by inducing direct cell death and antibody-dependent cell-mediated cytotoxicity. Obinutuzumab is under investigation in a wide-ranging program of clinical trials in patients with B-cell malignancies. Obinutuzumab may cause very serious infusion-related reactions during or up to 24 hours after treatment. These reactions occur more often with the first and second treatments. The drug is currently in Phase III stage of its development for the treatment of lupus nephritis.

* ADX-097: Q32 Bio

ADX-097 is based on a novel platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade, a key differentiator from current complement therapeutics. Q32 Bio completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers. Results from the Phase I clinical trial demonstrated a favorable tolerability and immunogenicity profile across all single and multiple dose cohorts and weekly subcutaneous dosing met exposures for predicted complete complement inhibition in the tissue with no systemic inhibition. Currently, the drug is in the Phase II stage of its development for the treatment of Lupus Nephritis.

* NKX019: Nkarta

NKX019 is designed to target CD19-positive B cells, which play a significant role in the pathogenesis of autoimmune diseases like lupus. The therapy utilizes NK cells derived from healthy donors that are genetically modified to enhance their ability to eliminate these B cells. Notably, NKX019 is engineered to express a membrane-bound form of interleukin-15, which may improve the persistence and activity of the NK cells without the need for extensive cytokine support typically required in other therapies. It is currently in Phase I stage of development for the treatment of Lupus Nephritis.

If you're tracking ongoing Lupus Nephritis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Lupus Nephritis Treatment Drugs [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Lupus Nephritis Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Lupus Nephritis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis Treatment.
* Lupus Nephritis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Lupus Nephritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lupus Nephritis market.

Lupus Nephritis Companies

Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics, Annexon, Century Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, Inflection Biosciences and others.

Lupus Nephritis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Lupus Nephritis Products have been categorized under various Molecule types such as,

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Lupus Nephritis Pipeline Report covers it all - check it out now @ Lupus Nephritis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Lupus Nephritis Pipeline Report

* Coverage- Global
* Lupus Nephritis Companies- Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics, Annexon, Century Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, Inflection Biosciences and others.
* Lupus Nephritis Therapies- Ciclesonide, Niclosamide, Povetacicept, APL-2, Belimumab Injection, AZD0120, Cyclophosphamide, Fludarabine, AZD0120, Abetimus sodium (LJP 394) , and others.
* Lupus Nephritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Lupus Nephritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Lupus Nephritis Treatment landscape in this detailed analysis @ Lupus Nephritis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Lupus Nephritis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Lupus Nephritis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Obinutuzumab: Hoffmann-La Roche
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ADX-097: Q32 Bio
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* NKX019: Nkarta
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Lupus Nephritis Key Companies
* Lupus Nephritis Key Products
* Lupus Nephritis- Unmet Needs
* Lupus Nephritis- Market Drivers and Barriers
* Lupus Nephritis- Future Perspectives and Conclusion
* Lupus Nephritis Analyst Views
* Lupus Nephritis Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lupus-nephritis-pipeline-outlook-report-2025-tracking-the-most-promising-drugs-in-clinical-development-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.